Equities researchers at Stifel Nicolaus began coverage on shares of GTx, Inc. (NASDAQ:GTXI) in a research report issued on Thursday, MarketBeat reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

Shares of GTx (GTXI) traded up $1.63 during trading hours on Thursday, reaching $10.30. The company’s stock had a trading volume of 67,600 shares, compared to its average volume of 82,008. GTx has a 52-week low of $2.73 and a 52-week high of $10.50.

GTx (NASDAQ:GTXI) last posted its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter. equities research analysts expect that GTx will post -1.35 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “GTx, Inc. (GTXI) Receives New Coverage from Analysts at Stifel Nicolaus” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/gtx-inc-gtxi-now-covered-by-stifel-nicolaus/1696820.html.

An institutional investor recently bought a new position in GTx stock. Bank of New York Mellon Corp purchased a new position in GTx, Inc. (NASDAQ:GTXI) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,355 shares of the biopharmaceutical company’s stock, valued at approximately $124,000. Bank of New York Mellon Corp owned 0.15% of GTx as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 9.00% of the company’s stock.

About GTx

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.